An abuse liability assessment of the glo tobacco heating product in comparison to combustible cigarettes and nicotine replacement therapy
Rattachement africain : ca, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Tobacco heating products (THPs) have reduced emissions of toxicants compared with cigarette smoke, and as they expose user to lower levels than smoking, have for a role to play in tobacco harm reduction. One key concern of Public Health is that new tobacco and nicotine products should not be more addictive than cigarettes. To assess their abuse liability, we determined nicotine pharmacokinetics and subjective effects of two THPs compared with conventional cigarettes and a nicotine replacement therapy (Nicotine inhaler). In a randomised, controlled, open-label, crossover study healthy adult smokers used a different study product in a 5 min ad libitum use session in each of four study periods. Product liking, overall intent to use again, urge for product and urge to smoke questionnaires were utilised to assess subjective effects. Nicotine uptake was greater for the cigarette (Cmax = 22.7 ng/mL) than for either THP (8.6 and 10.5 ng/mL) and the NRT (2.3 ng/mL). Median Tmax was significantly longer for the NRT (15.03 minutes) than for the tobacco products (4.05–6.03 minutes). Product liking and overall intent to use again was highest for the cigarette, and higher for the THPs than the NRT. Urge to smoke was reduced more by the cigarette than by the other three products. Urge to use the THPs was greater than the NRT. These findings suggest that the abuse liability of the THPs lies between that of subjects usual brand cigarettes and the NRT.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- An abuse liability assessment of the glo tobacco heating product in comparison to combustible cigarettes and nicotine replacement therapy
- Date Crossref
- 18/07/2022
- Éditeur
- Research Square Platform LLC
- Type
- posted-content
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
British American Tobacco (Canada) pays non établi dans la noticeEntreprise
-
Reynolds American (United States) pays non établi dans la noticeEntreprise
-
British American Tobacco (Investments) Limited pays non établi dans la noticeInstitution
-
Centro Ricerche Cliniche di Verona pays non établi dans la noticeÉtablissement de santé
-
DoctorProctorScience Limited pays non établi dans la noticeInstitution
-
R. J. Reynolds Tobacco Company pays non établi dans la noticeEntreprise
British American Tobacco (Canada), Reynolds American (United States) et British American Tobacco (Investments) Limited, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.